Depo-Provera Lawsuit Update May 2026: Daubert Hearings and MDL Status

Published by: Mason Arnao | Primary Sources: JPML MDL docket records, FDA drug safety records.

The Depo-Provera lawsuit update for May 2026 brings critical new developments that every Depo-Provera user diagnosed with meningioma must know. As of this month, MDL 3140 — the consolidated federal litigation against Pfizer in the Northern District of Florida — has grown to more than 3,769 active cases and is advancing through Daubert hearings that will determine the trajectory of all claims. Additionally, statutes of limitations are now actively running for victims diagnosed in 2023 and early 2024, making immediate action more urgent than ever. Call 855-664-8713 or start your free Depo-Provera case evaluation today — the window to file is closing.

Depo-Provera Lawsuit Update: May 2026 Key Summary

Here is what has happened in the Depo-Provera meningioma lawsuit leading up to May 2026 — and what it means for victims who have not yet filed:

• MDL 3140 has 3,769+ active cases as of May 2026 — making it one of the top 10 largest active federal pharmaceutical MDLs
• Daubert hearings are underway — the court is evaluating the admissibility of expert scientific testimony on the Depo-Provera meningioma link
• FDA meningioma warning label is in effect — Pfizer was required to update Depo-Provera labeling to disclose meningioma risk
• Statutes of limitations are actively running — victims diagnosed in 2023 or early 2024 may have less than a year to file in many states
• No settlement amounts are public — a global agreement followed in June 2026, and the July 21, 2026 Master Settlement Agreement is confidential
• No global settlement as of May 2026 — one was reached in June 2026, and the first bellwether trial was vacated

Additionally, the Depo-Provera MDL is notable for its diverse plaintiff population — women who used Depo-Provera for birth control across a wide range of ages, occupations, and demographic groups. Many were unaware until recently of the established scientific link between their injection and their meningioma diagnosis. This is precisely why TortAdvisor updates this page monthly: to ensure that no victim misses their opportunity to pursue compensation through the Depo-Provera legal process.

MDL 3140: Current Status & Daubert Hearings May 2026

MDL 3140 — formally In re: Depo-Provera (Medroxyprogesterone Acetate) Products Liability Litigation — is proceeding in the Northern District of Florida under Judge M. Casey Rodgers. The most significant current development is the Daubert hearing phase, which represents one of the most pivotal moments in the litigation’s trajectory. During Daubert proceedings, the presiding judge evaluates whether the plaintiff’s scientific experts meet the Daubert reliability standard for testifying about causation — specifically, whether medroxyprogesterone acetate (MPA) causes meningioma at a rate exceeding chance, through a scientifically valid and peer-reviewed methodology.

Plaintiffs’ experts are expected to draw on the 2024 BMJ study, NIH meningioma progesterone receptor research, epidemiological cohort data, and clinical observations of meningioma regression upon Depo-Provera discontinuation. The FDA’s label update is also likely to be central to plaintiffs’ case: it establishes that the scientific consensus on meningioma risk was sufficient to require regulatory action, which directly supports the failure-to-warn liability theory. A favorable Daubert ruling for plaintiffs would unlock the bellwether trial phase, in which a representative set of Depo-Provera meningioma cases are tried to verdict — establishing a template for the broader settlement. Consequently, the Daubert outcome is the single most important near-term event for all MDL 3140 plaintiffs. Official case information is available through the Judicial Panel on Multidistrict Litigation and CourtListener.

What Changed in 2026: FDA, Pfizer & Court Developments

Several significant developments have shaped the Depo-Provera meningioma landscape in 2026. Understanding these updates is essential context for evaluating your legal position and acting appropriately. First, the FDA meningioma warning label update is now fully in effect. Pfizer’s Depo-Provera prescribing information and patient labeling now explicitly discloses the association between long-term MPA use and increased meningioma risk. This update — while it does not resolve the litigation — is a significant acknowledgment that validates the core of every plaintiff’s failure-to-warn claim. Second, Pfizer is producing internal documents in response to MDL discovery orders, including pre-marketing clinical study data, post-market safety monitoring records, and internal communications about the meningioma signal. These documents are expected to be central to the bellwether trial evidence and may contain admissions that substantially strengthen plaintiffs’ cases. Third, the MDL bellwether pool has been selected, and trial scheduling orders are expected to follow favorable Daubert rulings. The bellwether trials will be the first to answer: how does a jury view Pfizer’s liability, and what do they consider fair compensation for a Depo-Provera meningioma victim?

Furthermore, the FDA has been increasingly focused on progestin safety more broadly, following regulatory actions in France and other European countries where high-potency progestins were already restricted or required enhanced warnings years before U.S. action. This context strengthens the argument that Pfizer should have acted sooner — and that the delay in warning U.S. patients caused demonstrable harm to thousands of women. Additionally, Pfizer has not yet announced any settlement fund or global resolution, which means victims who file now will be positioned for the earliest phase of settlement discussions when negotiations begin.

Statute of Limitations: Depo-Provera Deadlines You Cannot Miss

The statute of limitations for the Depo-Provera meningioma lawsuit is one of the most critical — and most misunderstood — aspects of this litigation. Here is what you need to know as of May 2026:

• Most states: 2–3 years from the date of meningioma diagnosis, OR from the date you discovered (or reasonably should have discovered) the connection to Depo-Provera
• Discovery rule: Many states apply the “discovery rule,” which delays the start of the limitations period until you knew or should have known of the drug link — this may extend deadlines for victims diagnosed before the FDA warning
• Wrongful death: Statutes of limitations for wrongful death claims vary by state and are typically measured from the date of death — different from personal injury deadlines
• No federal tolling: MDL consolidation does NOT automatically toll (pause) individual state statutes of limitations — you must file your individual complaint to preserve your rights
• Diagnosis in 2022–2023: If you were diagnosed with meningioma in 2022 or 2023, your statute of limitations may be expiring NOW in many states — contact an attorney immediately

The single most dangerous mistake a Depo-Provera meningioma victim can make is assuming they have more time. Statutes of limitations are rigid, court-enforced deadlines — once they pass, even the most compelling case is permanently barred from receiving compensation. Call 855-664-8713 now, or visit our Depo-Provera lawsuit guide to confirm your specific deadline.

Who Still Qualifies to File a Depo-Provera Lawsuit in May 2026?

As of May 2026, a significant number of Depo-Provera meningioma victims still qualify to file. The core criteria remain: 12+ months of Depo-Provera use; confirmed meningioma diagnosis (any grade); drug use preceding the diagnosis; and being within your state’s statute of limitations. However, the urgency for victims with earlier diagnosis dates is intensifying rapidly.

• Diagnosed 2024–2026: Very likely still within filing window — act promptly
• Diagnosed 2023: Filing window is closing in most states — contact attorney immediately
• Diagnosed 2022: May be outside limitations in some states without discovery rule — urgent legal consultation needed
• Diagnosed pre-2022: Potentially time-barred in many states; however, the discovery rule may still preserve your claim if you only recently learned of the Depo-Provera connection
• Wrongful death: Deadlines measured from date of death — consult attorney immediately regardless of when the death occurred

Depo-Provera Settlement Amounts: What Is Public in 2026

A global settlement agreement was reached in June 2026, after this update was first published, and the Master Settlement Agreement signed on July 21, 2026 is confidential. No total fund, payout matrix or per-person amount has been made public, so any range you see online is an estimate, not a reported figure. The deadline for claimants to register is November 30, 2026. Review all mass tort settlement data at TortAdvisor. Related cases experienced attorneys handle include Ozempic lawsuits, talcum powder lawsuits, and hair relaxer lawsuits.

How to Join the Depo-Provera Lawsuit in May 2026

1. Free Evaluation: Call 855-664-8713 or submit online — 5 minutes, completely free.
2. Records Gathering: Your legal team assists in obtaining Depo-Provera prescription records and meningioma imaging/pathology documentation.
3. Retain MDL Attorney: Contingency fee only — you pay nothing unless you win.
4. File in MDL 3140: Your complaint is filed in the Northern District of Florida — no court appearance needed.
5. Settlement Registration: Eligible claimants must register for the settlement program by November 30, 2026; payments are expected to begin by the first quarter of 2027.

Use Our Free Depo-Provera Settlement Calculator

Before you call, get an estimate of your claim value using our free Depo-Provera settlement calculator. It takes under two minutes.

Frequently Asked Questions: Depo-Provera Lawsuit Update 2026

About the Author

My name is Mason Arnao, and my background in data systems, technology infrastructure, and digital advocacy has given me a deep understanding of how the Depo-Provera lawsuit update 2026 affects real people navigating complex legal and medical systems. As publisher of TortAdvisor.com and President of Waypoint Software — a leading digital firm with over 20 years of experience — I’ve built systems that connect people with critical information. This page is updated monthly with the latest developments in the Depo-Provera meningioma litigation.